John King, MBA

John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, John led the organization in preparing for a global commercial launch. Prior to Ra Pharma, he was Vice President, U.S. Neurology Business Unit, at Alexion Pharmaceuticals where he was responsible for building and leading the team that launched Soliris® (eculizumab) for gMG. At Alexion, he also served roles of increasing responsibility, including Vice President, Head of Global LAL-D Franchise and Vice President, Head of Global Hematology Franchise. Before joining Alexion in 2009, John served in commercial roles of increasing responsibility at Wyeth Pharmaceuticals, including Product Director of Enbrel® (etanercept). He began his career at Ernst & Young LLP. John obtained his B.S. in business logistics and MBA from the Pennsylvania State University.